INTERFERON COMPOSITION FOR ENHANCING THE PLATELET COUNT, REDUCING THE RECURRENCE RATE OF HEPATITIS, AND IMPROVING THE SOCIAL FUNCTION OF HEPATITIS PATIENTS
CHEN, YE SHYON,陈奕雄,陳奕雄,LEE, CHING YUAN,李清源,李清源,CHEN, STEPHEN T.,陈德芳,陳德芳,YEH, CHAU TING,叶昭廷,葉昭廷,CUMMINS, MARTIN J.,康明斯 马丁J,康明斯 馬丁J
申请号：
TW102109473
公开号：
TW201436803A
申请日:
2013.03.18
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
The present invention relates to an interferon composition, which has medical uses of enhancing the platelet count, reducing the recurrence rate of hepatitis, and improving the social function of hepatitis patients. The composition comprises two interferons, and each of the two interferons are a type I interferon IFN-α. Moreover, after 48-week’s clinical trial being finished, the experiment results show that the Recurrence rate of hepatitis of the hepatitis C patients taking the interferon composition 500 UI per day is reduced with the percentage of 8.3% (the control group’s is 41.7%) In addition, the platelet count of the hepatitis C patients is enhanced with the percentage of 81% (the control group’s is 41.7%), and the social function of the hepatitis C patients reaches to 21 scores. Therefore, the experiment results of the clinical trial are able to prove that the interferon composition indeed has the medical uses of enhancing the platelet count, reducing the recurrence rate of hepatitis, and improving the social function of hepatitis patients.本發明係關於一種干擾素組合物,具有提升血小板數目、降低肝炎病患之復發率以及增進其社交功能之新用途。本組合物包含有兩種干擾素,皆為由病毒誘發白血球細胞所獲得之第一型干擾素IFN-α。並且,經48週的臨床試驗驗證,每日服用本干擾素組合物500國際單位,係可將C型肝炎病患之肝炎復發率降低至8.3%(對照組為41.7%);此外,該C型肝炎病患之血小板數量可恢復至81%左右(對照組為40.6%),同時其社交功能的分數達到21分(對照組為9.7分);因此,經由臨床實驗數據可證明本組合物具有提升血小板數目、降低肝炎病患之復發率以及增進其社交功能之新用途。
